摘要
目的探讨TP方案联合曲妥珠单抗靶向治疗人表皮生长因子受体2(HER2)阳性乳腺癌的疗效。方法将70例HER2阳性乳腺癌患者按治疗方法不同分为观察组及对照组,每组35例,观察组患者给予多西他赛+卡铂(TP方案)联合曲妥珠单抗治疗,对照组患者给予TP方案化疗。比较两组患者临床疗效、肿瘤标志物水平以及不良反应发生情况。结果观察组患者总有效率为82.86%,高于对照组的54.29%,差异有统计学意义(P﹤0.05)。治疗前,两组患者癌胚抗原(CEA)、转化生长因子-β1(TGF-β1)、血管内皮生长因子(VEGF)、肿瘤特异性生长因子(TSGF)水平比较,差异均无统计学意义(P﹥0.05);治疗后,两组患者CEA、TGF-β1、VEGF、TSGF水平均下降,差异均有统计学意义(P﹤0.05),且观察组患者CEA、TGF-β1、VEGF、TSGF水平均明显低于对照组,差异均有统计学意义(P﹤0.01)。两组患者各不良反应发生情况比较,差异均无统计学意义(P﹥0.05)。结论TP方案联合曲妥珠单抗靶向治疗HER2阳性乳腺癌临床疗效显著,且可有效降低相关血清肿瘤标志物水平,安全性理想。
Objective To investigate the evaluation of efficacy on TP regimen combined with trastuzumab in the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer. Method 70 cases of patients with HER2 positive breast cancer were divided into observation group and control group, with 35 cases in each. The patients in observation group were administered docetaxel+carboplatin (TP regimen) combined with trastuzumab, the patients in control group were administered TP regimen. The clinical efficacy, levels of tumor markers and occurrence of adverse reactions were compared. Result The overall response rate of observation group was 82.86%, and 54.29% in the control group, with statistically significant difference (P<0.05). Before treatment, the differences of carcinoembryonic antigen (CEA), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF) and tumor specific growth factor (TSGF) in two groups were not statistically significant (P>0.05). After treatment, the levels of CEA, TGF-β1, VEGF, TSGF decreased in both groups, and the differences were statistically significant (P<0.05), with significant lower levels of CEA, TGF-β1, VEGF, TSGF in observation group than those in the control group (P<0.01). No significant differences of adverse reactions in two groups were observed (P>0.05). Conclusion Targeting treatment of TP regimen combined with trastuzumab in HER2 positive breast cancer is effective, which can decrease the levels of related serum tumor markers, and the safety is adequate.
作者
尹子毅
张铁
曲更宝
YIN Ziyi;ZHANG Tie;QU Gengbao(Department of Breast Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China)
出处
《癌症进展》
2019年第12期1391-1394,共4页
Oncology Progress
关键词
人表皮生长因子受体2阳性
乳腺癌
靶向治疗
疗效
human epidermal growth factor receptor 2 positive
breast cancer
targeting treatment
efficacy
